Paracetamol IV (intravenous paracetamol) is a formulation of the well-known pain reliever and fever reducer paracetamol (often referred to as acetaminophen) designed for intravenous injection. It is mostly used in clinical settings to treat moderate to severe pain, particularly after surgery, and to lower fever in hospitalized patients. Because the intravenous version acts quickly, it is very beneficial for postoperative patients who require prompt and effective pain control. It is a safer alternative to opioids since it reduces the demand for medications to manage pain.
According to SPER market research, ‘Global Paracetamol IV Market Size- By Indication, By Application, By End Use – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Paracetamol IV Market is predicted to reach 1150.18 million by 2034 with a CAGR of 3.72%.
Drivers:
The primary reasons for the growth of the intravenous paracetamol market are its use in pain management, particularly in post-operative care, and fever control. In particular, for those who are unable to take oral medications, intravenous paracetamol is a great therapy option that eliminates pain rapidly and efficiently. It is increasingly being used as part of a multimodal approach to pain management in combination with NSAIDs and opioids, in line with the increasing need for comprehensive pain relief choices. The growing demand for non-opioid alternatives, especially as the number of surgical procedures increases, benefits the industry. Intravenous paracetamol improves patient outcomes and speeds up recovery by precisely relieving pain and reducing opioid dependence. Countries.
Restraints:
The potential for side effects like hepatotoxicity and anaphylaxis is a major barrier in the global market for intravenous paracetamol, which makes doctors use it cautiously. Ongoing research is necessary to determine acceptable dosage guidelines and ensure long-term safety. Manufacturers must focus on post-marketing surveillance and healthcare professional training in order to boost trust in its use.
Request a Free Sample Report: https://www.sperresearch.com/report-store/paracetamol-IV-market.aspx?sample=1
The strong need for pain management in surgical and hospital settings is driving the North American market for intravenous paracetamol. Growing surgical procedures, regulatory support, and sophisticated healthcare infrastructure all fuel market expansion. Its position is strengthened by strategic alliances and formulation advancements, with an increasing emphasis on non-opioid substitutes.
Some significant market players are Abbott, Aurobindo Pharma, Bristol-Myers Squibb Company, Cipla Inc., Dr Reddy’s Laboratories Ltd., Lupin, Mallinckrodt (Mallinckrodt Pharmaceuticals).
For More Information, refer to below link: –
Related Reports:
Follow Us –
LinkedIn | Instagram | Facebook | Twitter
Contact Us:
Sara Lopes, Business Consultant — USA
SPER Market Research
enquiries@sperresearch.com
+1–347–460–2899
Leave a Reply